<DOC>
	<DOCNO>NCT01634945</DOCNO>
	<brief_summary>The propose project aim test two intervention , namely highly bioavailable iron compound combination SP plus amodiaquine intermittent preventive treatment ( IPT ) malaria , reduce anaemia young child .</brief_summary>
	<brief_title>Efficacy Iron Fortified Complementary Food IPT Malaria Young Children Côte d'Ivoire</brief_title>
	<detailed_description>Efficacy study - ANAEMIA project Côte d'Ivoire The propose project aim test two intervention , namely highly bioavailable iron compound combination SP plus amodiaquine intermittent preventive treatment ( IPT ) malaria , reduce anaemia young child . The fortified product provide porridge ( Nutribon produce PKL ) optimize formula ( 2 mg form NaFeEDTA 3.8 mg form ferrous fumarate ) premix . In addition , assess Nutribon product currently available market compare optimize premix formula . The current optimized formula contain 2 mg iron form NaFeEDTA . In addition NaFeEDTA current premix contain 3.8 mg form ferric pyrophosphate , less bioavailable 3.8 mg ferrous fumarate optimize formula . The study carry May December 2012 include rainy season ( April - October ) two peak Côte d'Ivoire thus period malaria transmission high . The study implement Health Demographic Surveillance System Taabo Côte d'Ivoire comprise 625 child 12 36 month . 375 eligible infant receive fortify porridge ( 250 improve formula 125 current formula ) , whereas 250 infant continue local diet ( control group ) . Infants receive optimized formula infant control group randomly assign IPT malaria ( 125 group ) placebo ( 125 group ) . Thus , infant assign one follow five group : 1. group ( n=125 ) : fortify porridge ( optimized formula ) IPT malaria 2. group ( n=125 ) : fortify porridge ( optimized formula ) placebo 3. group ( n=125 ) : local diet IPT malaria 4. group ( n=125 ) : local diet placebo . 5. group ( n=125 ) : fortify porridge ( current formula ) placebo , represent current situation Côte d'Ivoire infant consume fortify complementary food . This efficacy trial deepen understand prevent anaemia interaction bioavailable iron compound antimalarial drug relate condition young child . Further , study demonstrate whether early study fail show impact anaemia due use iron compound lack bioavailability and/or use antimalarial drug IPT intervention arm lack efficacy perhaps due resistance P. falciparum , yet investigate cause .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferrous fumarate</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<criteria>Children , age 12 36 month , sex Absence major systemic illness ( assessed medical doctor upon initial full clinical assessment ) Registered DSS Taabo anticipate residence study area least 1 year No severe anaemia , i.e . Hb ≥70 g/L infant , assess Coulter Counter device No known report hypersensitivity sulfadoxinepyrimethamine , amodiaquine No known report history significant chronic illness Written inform consent parent legal guardian severe anaemia , i.e . Hb ≥70 g/L infant , assess Coulter Counter device major systemic illness ( assessed medical doctor upon initial full clinical assessment ) know report hypersensitivity albendazole , sulfadoxinepyrimethamine , amodiaquine know report history significant chronic illness</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>36 Months</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>anemia</keyword>
	<keyword>malaria</keyword>
	<keyword>malnutrition</keyword>
	<keyword>iron fortification</keyword>
	<keyword>intermittent preventive treatment</keyword>
	<keyword>subsaharan africa</keyword>
	<keyword>ivory coast</keyword>
	<keyword>young child</keyword>
</DOC>